Avantor vs Charles River Laboratories
Avantor reported revenue of $6.6 billion in fiscal 2025, 1.6 times Charles River Laboratories' $4.0 billion in fiscal 2025. Avantor's revenue fell 3.4% in its latest year, and Charles River Laboratories' fell 0.8%. Avantor had an operating margin of -3.8%, against 0.6% at Charles River Laboratories. Free cash flow was $495 million at Avantor and $518 million at Charles River Laboratories. Their fiscal years end in different months (December 31 and December 27), so the periods don't line up exactly.
Side by side
| Avantor | Charles River Laboratories | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 27, 2025 |
| Revenue | $6.6B | $4.0B |
| Revenue growth | −3.4% | −0.8% |
| Revenue growth a year, last 5 years | 0.5% | 6.5% |
| Gross margin | 32.6% | — |
| Operating margin | −3.8% | 0.6% |
| Net margin | −8.1% | −3.6% |
| Free cash flow | $495M | $518M |
| Free cash flow margin | 7.5% | 12.9% |
| Return on capital | −2.0% | 0.4% |
| Net debt to EBITDA | 22.0x | 4.5x |
| Dividends and buybacks | $75M | $361M |
| Change in diluted share count | −0.2% | −4.0% |
| Last close | $17.29 | $357.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $8.7 million, sold $0 | bought $7,338, sold $52.1 million |
| Piotroski F-score | 5 of 9 | 4 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AvantorCharles River Laboratories
Operating margin
Percent of revenue
AvantorCharles River Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AvantorCharles River Laboratories
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Avantor and Charles River Laboratories pages.